Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Chester

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Nature Biotechnology|March 5, 2002
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cellsJohn Chester, Anja Ruchatz, Michael Gough, et al.
BJU International|April 27, 2020
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatinRobert Jones, Simon Crabb, John Chester, et al.
The Journal of Clinical Investigation|April 6, 2010
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in miceTimothy Kottke, Geoff Hall, Jose Pulido, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 28, 2011
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapyTimothy Kottke, John Chester, Elizabeth Ilett, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Cancer Research|June 18, 2003
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapyMarka Crittenden, Michael Gough, John Chester, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic VirusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
European Urology|December 4, 2014
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinomaThomas Geldart, John Chester, Angela Casbard, et al.
The Journal of Molecular Diagnostics : JMD|January 14, 2012
Next-generation sequencing for simultaneous determination of human papillomavirus load, subtype, and associated genomic copy number changes in tumorsCaroline Conway, Rebecca Chalkley, Alec High, et al.
Nature Medicine|June 21, 2011
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsTimothy Kottke, Fiona Errington, Jose Pulido, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Nature Biotechnology|March 5, 2002
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cellsJohn Chester, Anja Ruchatz, Michael Gough, et al.
BJU International|April 27, 2020
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatinRobert Jones, Simon Crabb, John Chester, et al.
The Journal of Clinical Investigation|April 6, 2010
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in miceTimothy Kottke, Geoff Hall, Jose Pulido, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 28, 2011
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapyTimothy Kottke, John Chester, Elizabeth Ilett, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 24, 2008
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
Cancer Research|June 18, 2003
Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapyMarka Crittenden, Michael Gough, John Chester, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 9, 2017
Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic VirusTimothy Kottke, Feorillo Galivo, Phonphimon Wongthida, et al.
European Urology|December 4, 2014
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinomaThomas Geldart, John Chester, Angela Casbard, et al.
The Journal of Molecular Diagnostics : JMD|January 14, 2012
Next-generation sequencing for simultaneous determination of human papillomavirus load, subtype, and associated genomic copy number changes in tumorsCaroline Conway, Rebecca Chalkley, Alec High, et al.
Nature Medicine|June 21, 2011
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsTimothy Kottke, Fiona Errington, Jose Pulido, et al.
Pageof 4